INDICATIONS FOR TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE)

**General Criteria** (Doherty 2019, Flachskampf 2014, Hahn 2013, Lancelotti 2013, Ogbara 2011)
- TEE may be performed after a nondiagnostic TTE or a high likelihood of a nondiagnostic TTE due to patient characteristics or inadequate visualization of relevant structures

**Aortic Pathology**
- Suspected acute aortic pathology such as aortic dissection (Bhave 2018, Doherty 2019)
- Dilated aortic sinuses or ascending aorta on transthoracic echocardiogram (TTE)
- Evaluation of aortic sinuses, sinotubular junction, or ascending aorta in patients with bicuspid aortic valve when morphology cannot be assessed by TTE, and other imaging including CT or MRI have not been done

**Valvular Disease** (Doherty 2017, Nishimura 2014)
- Discordance between clinical assessment and TTE assessment of the severity of mitral regurgitation (MR)
- Evaluation of mitral stenosis, when there is a discrepancy between clinical signs or symptoms, and TTE is inadequate
- Discordance between clinical assessment and TTE assessment of the severity of aortic regurgitation (AR)
- Evaluation of native or prosthetic valves with clinical signs or symptoms suggesting valve dysfunction, when TTE is inadequate
- Re-evaluation of known prosthetic valve dysfunction when it would change management or guide therapy, and TTE is inadequate

**Infective Endocarditis** (Doherty 2017, Douglas 2011, Saric 2016)
- Suspected infective endocarditis (IE) of native valve, prosthetic valve, or endocardial lead with positive blood culture or new murmur
- Moderate to high pretest probability of IE (i.e. staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device) when TTE is negative
- Re-evaluation of IE in a patient with a change in clinical status or cardiac examination (e.g. new murmur, embolism, persistent fever, heart failure (HF), abscess, or atrioventricular block)
- Re-evaluation of IE if the patient is at high risk for progression/complications or when the findings would alter therapy, when TTE is inadequate

**Cardiac Mass or Source of Emboli**
- Evaluation of cardiac mass, suspected tumor or thrombus, or potential cardiac source of emboli (Doherty 2019, Saric 2016)
• Re-evaluation of prior TEE finding for interval change (e.g. resolution of thrombus after anticoagulation) when the findings would change therapy

Atrial Fibrillation/Flutter (January 2019)
• Evaluation for clinical decision making regarding anticoagulation, cardioversion, and/or radiofrequency ablation

TAVR (Transcatheter Aortic Valve Replacement/Repair) (Doherty 2017, Otto 2017)
• Pre-procedural assessment of annular size and shape, number of cusps, and degree of calcification, when computed tomography (CT) cannot be performed
• Post procedural assessment of degree of aortic regurgitation (including valvular and paravalvular) with suspicion of valve dysfunction, if TTE is inadequate

Patent Foramen Ovale or Atrial Septal Defect (Doherty 2019)
• Evaluation for anatomy, potential cardiac source of emboli, and suitability for percutaneous device closure
• Evaluation post device closure with clinical concern for infection, malposition, embolization or persistent shunt

Left Atrial Appendage Occlusion (Doherty 2019)
• Evaluation for anatomy, potential cardiac source of emboli, and suitability for percutaneous occlusion device placement
• Surveillance at 45 days or FDA guidance/guidelines for follow-up to assess device stability and device leak, and exclude migration, displacement, or erosion

Percutaneous Mitral Valve Repair (Doherty 2017)
• Determination of patient eligibility for percutaneous mitral valve procedures
• Pre-procedural evaluation for percutaneous mitral valve procedures may be performed in addition to CT imaging (Wunderlich 2018)
• Exclude the presence of intracardiac mass, thrombus, or vegetation prior to (within 3 days of) the procedure

Adult Congenital Heart Disease (Stout 2018)
• Imaging with provocative maneuvers (Valsalva, cough) to assess for the presence of right-to-left cardiac shunt
• Evaluation when TTE, CMR, or CTA are not adequate in the setting of:
  o Pulmonary venous connections with ASD
  o Aortic imaging in Williams syndrome or patient suspected of having supravalvular stenosis
  o Surgical planning for Ebstein anomaly
  o Evaluation of baffle leak after atrial switch repair for d-Transposition of the Great Arteries

Ventricular Assist Devices (Doherty 2019, Stainback 2015)
• Preoperative evaluation of suitability for ventricular assist device (VAD)
• Re-evaluation for VAD-related complication or suspected infection
BACKGROUND:
Transesophageal echocardiography (TEE) enables cardiac ultrasound imaging from within the esophagus, which provides a window for enhanced quality images as well as additional views, beyond that acquired by standard transthoracic echocardiography (TTE).

Abbreviations

- AR: aortic regurgitation
- CMR: cardiac magnetic resonance
- CT(A): computed tomography (angiography)
- IE: infective endocarditis
- MR: mitral regurgitation
- MRI: magnetic resonance imaging
- TEE: transesophageal echocardiography
- TTE: transthoracic echocardiography
- VAD: ventricular assist device
POLICY HISTORY:
Review Date: July 26, 2019

Review Summary:

- For ventricular assist devices added indication for re-evaluation for VAD-related complication or suspected infection
- Aortic Pathology section rewritten as follows:
  - Suspected acute aortic pathology such as aortic dissection (Bhave 2018, Doherty 2019)
  - Dilated aortic sinuses or ascending aorta on transthoracic echocardiogram (TTE)
  - Evaluation of aortic sinuses, sinotubular junction, or ascending aorta in patients with bicuspid aortic valve when morphology cannot be assessed by TTE, and other imaging including CT or MRI have not been done
- Added infective endocarditis indication for moderate to high pretest probability of IE (i.e. staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device) when TTE is negative
- For cardiac mass or source of emboli added indication for re-evaluation of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation) when the findings would change therapy
- Added indications for Patent Foramen Ovale or Atrial Septal Defect as follows:
  - Evaluation for anatomy, potential cardiac source of emboli, and suitability for percutaneous device closure
  - Evaluation post device closure with clinical concern for infection, malposition, embolization or persistent shunt
- Added indications for Left Atrial Appendage Occlusion as follows:
  - Evaluation for anatomy, potential cardiac source of emboli, and suitability for percutaneous occlusion device placement
  - Surveillance at 45 days or FDA guidance/guidelines for follow-up to assess device stability and device leak, and exclude migration, displacement, or erosion
- Added indications for Adult Congenital Heart Disease as follows:
  - Imaging with provocative maneuvers (Valsalva, cough) to assess for the presence of right-to-left cardiac shunt
  - Evaluation when TTE, CMR, or CTA are not adequate in the setting of:
    - Pulmonary venous connections with ASD
    - Aortic imaging in Williams syndrome or patient suspected of having supravalvular stenosis
    - Surgical planning for Ebstein anomaly
    - Evaluation of baffle leak after atrial switch repair for d-Transposition of the Great Arteries
    - Removed section on “Frequency of Echo Studies”
REFERENCES


Reviewed / Approved by Patrick Browning, VP, Medical Director

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.